The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer

J Ovarian Res. 2019 Feb 4;12(1):12. doi: 10.1186/s13048-019-0488-2.

Abstract

Background: The aim of this study was to (1) evaluate the ability of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) parameters to predict suboptimal cytoreduction and (2) to create a risk model for predicting suboptimal cytoreduction in advanced ovarian cancer. From 2011 to 2015, 51 patients underwent primary cytoreductive surgery for advanced ovarian cancer were enrolled. A residual disease with maximal diameter > 1 cm was considered a suboptimal surgical result. The SUVmax values for nine abdominal regions, the sum of 9 regional SUVmax (WB1SUVmax) and WB2SUVmax (WB1SUVmax plus SUVmax of lymph nodes) were used for PET parameter. Multiple logistic regression analysis was used to determine the predictive value of PET and clinical parameters for risk model. In addition, assessments of disease-free survival (DFS) and overall survival (OS) were performed.

Results: Seventeen of the 51 patients (33.3%) underwent suboptimal cytoreduction. The ECOG status (OR, 4.091), SUVmax of central (OR, 5.250), right upper (OR, 4.148), left upper (OR, 5.921) and WB2SUVmax (OR, 4.148) were associated with suboptimal cytoreduction. The risk model can divide the risk groups of suboptimal cytoreduction (area under the curve (AUC), 0.775; p = 0.0001). The DFS and OS in the high-risk group were significantly worse than those in the low-risk group (p = 0.0379 for DFS; p = 0.0211 for OS).

Conclusions: The presence of hypermetabolic lesions in the central, right upper, and left upper regions showed predictive value for suboptimal cytoreduction. Our risk model may be helpful for selecting patients who may show suboptimal cytoreduction.

Keywords: Advanced ovarian cancer; FDG PET/CT; Risk model; SUVmax; Suboptimal cytoreduction.

MeSH terms

  • Adult
  • Aged
  • Cytoreduction Surgical Procedures
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Middle Aged
  • Models, Biological*
  • Ovarian Neoplasms / diagnostic imaging*
  • Ovarian Neoplasms / surgery*
  • Positron Emission Tomography Computed Tomography
  • Radiopharmaceuticals
  • Risk

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18